{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Number of patients meeting the composite endpoint of 1) febrile neutropenia (grade 3 or 4), 2) major bleeding with concurrent grade 3 thrombocytopenia (platelet count \\<50,000/mm3), 3) CTCAE grade 4 neutropenia (ANC \\<500/mm3), and/or 4) CTCAE grade 4 thrombocytopenia (platelet count \\<25,000/mm3)","groups":[{"description":"All participants enrolled in the study - includes participants who were not evaluable for the primary study outcome","id":"OG000","title":"All Enrolled Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Through day 1 of cycle 6 of FOLFOX chemotherapy (cycle length is 14 days)","title":"Composite Safety Endpoint","type":"SECONDARY","unitOfMeasure":"Participants"}